by
Barbara Kram, Editor | August 13, 2008
MEDRAD's Continuum
MR Infusion System
Wireless Remote
Display
WARRENDALE, PA -- MEDRAD, INC. has announced that the wireless version of its Continuum MR Infusion System has received U.S. Food and Drug Administration (FDA) 510(k) clearance.
The new Continuum Wireless MR Infusion System enables the clinician to control a patient's medication infusion during a magnetic resonance (MR) procedure from both inside and outside the scan room. When changes are needed, including flow rate, bolus, or to start or stop the infusion altogether, clinicians can control these parameters without interrupting the MRI scan with a new wireless remote display featuring a color touch screen. This option will increase workflow efficiencies and throughput while enhancing clinician confidence by enabling easy selection from up to nine IV stands, minimizing scan interruptions due to infusion changes and displaying all infusion parameters.
Joe Havrilla, sr. vice president, MEDRAD MR "The Continuum Wireless is designed to produce efficiency and boost throughput in MRI, but it also builds confidence in the patient care staff that control of a patient's medication is always nearby, especially when implemented for applications like pediatric sedation," said Joe Havrilla, senior vice president, MEDRAD MR Business Unit.

Ad Statistics
Times Displayed: 19090
Times Visited: 362 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Continuum Wireless joins the Veris® MR Monitor as the second product to utilize MEDRAD's Certo™ MR Wireless Network.
The original Continuum MR Infusion System was introduced in 2002 as the first infusion system designed for the harsh electro-magnetic environment in MR. MEDRAD has designed an upgrade path to wireless for current Continuum users.
MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2007 revenues were $525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at www.medrad.com.
Bayer AG is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. The company's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well being and quality of life by diagnosing, preventing and treating diseases.
Back to HCB News